logo oncologia taormina
divisione oncologia medica ospedale san vincenzo taormina
associazione salus

MONOGRAFIE

  1. “Il carcinoma ovarico. Trattamenti integrati”
    • Domenico Priolo, Francesco Ferraù
    • Up Grade - Percorsi di Oncologia Clinica, Medicalink Publishers, 2004
  2. “Il dolore da cancro”
    • Francesco Ferraù, Marco Filippini, Sebastiano Mercadante, Davide Tassinari, Paolo Tralongo, Giorgio Trizzino
    • Centro Studi Mundipharma, Medicalink Publishers, 2006

PUBBLICAZIONI SOTTOFORMA DI COMUNICAZIONI A CONGRESSI (Abstracts, 2000 – 2006)

  1. “Prolonged infusional 5-fluorouracil (PIF) in colorectal cancer patients refractory to bolus 5-fluorouracil + folinic acid regimen: a retrospective series”,
    • Cordio S, Giuffrida D, Ferraù F, Lavenia G, Priolo D, Failla G
    • Abstracts del 1° Congresso Nazionale di Oncologia Medica 1999 (XXV Riunione Scientifica della Associazione Italiana di Oncologia Medica), Roma 24-28 Ottobre 1999, abst. 40, pag.15
  2. “Doxorubicin (DXR) + Docetaxel (DOC) as first line therapy of advanced breast cancer (ABC): results of a multicentric phase II study on 72 patients (PTS).”
    • Palmeri S, Leonardi V, Ferraù F, Failla G, Tamburo De Bella M, Gasparini G, Morabito A, Massidda B, Cascinu S, Segati A, Citarrella P, Miceli S
    • Abstracts del 1° Congresso Nazionale di Oncologia Medica 1999 (XXV Riunione Scientifica della Associazione Italiana di Oncologia Medica), Roma 24-28 Ottobre 1999, abst. 176, pag.62
  3. “Oral antiemetic treatment in preventing chemotherapy induced delayed CDDP emesis”
    • Tralongo P, Dimari A, Aiello R, Iacono C, Iacono G, Ferraù F, Vitello S, Failla G, Conti G
    • Proc.ASCO, 637a, abst. 2517, 2000
  4. “Attualità sul cervicocarcinoma. Terapia medica delle recidive.”
    • F.Ferraù , D.Priolo
    • Riassunti del “ 2° Congresso Mediterraneo di Scienze Ginecologiche”, Catania 25-27 Maggio 2000, pag. 18
  5. “A phase I study of weekly paclitaxel combined with protracted continuous infusion of 5FU in patients with advanced breast cancer, pretreated with anthracycline-containing regimens”
    • Cortesi E, Grifalchi F, Ramponi S, Moscetti L, Ferraù F, Oliva A
    • Ann Oncol 11 (suppl.4), 119P:29 , 2000
  6. “ Vinorelbine (VNB) and estramustine (EMP) in hormone-refractory prostate cancer (HRPC).”
    • Ferraù F, Morgia G, Priolo D, Vitale F, Parisi A, Mattina M, Calì S
    • Ann Oncol 11 (suppl.4), 339P:77, 2000
  7. “A phase I-II study of gemcitabine and vinorelbine as seconda line treatment of patients with metastatic breast cancer”
    • Fanelli M, Morabito A, Filippelli G, Vitale S, Palmeri S, Tamburo De Bella M, Giliberti S, Ferraù F, Massidda B, Cascinu S, Catalano V, Gasparini G
    • Ann Oncol 11(suppl.2), E2:35, 2000
  8. “A phase I study of weekly paclitaxel combined with protracted continuous infusion of 5FU in patients with advanced breast cancer, pretreated with anthracycline-containing regimens”
    • Cortesi E, Ramponi S, Oliva A, Ferraù F, Moscetti L and Grifalchi F
    • Ann Oncol 11 (suppl.2), E21 : 39, 2000
  9. “Chemioterapia di induzione nel carcinoma polmonare non microcitoma stadio IIIaN2”
    • Ferraù F, Malaponte E, Antonelli G
    • Proceedings of the 63rd Corse Advances in Oncology “Current perspectives on biomolecular indicators and clinical management of bladder, breast, colorectal and lung cancers”, Erice 18-22 Aprile 2001, p.51 (copia)
  10. “Raltitrexed (TOM) may replace the De Gramont regimen in combination with oxaliplatin (L-OHP) for the treatment of advanced colorectal cancer”
    • Catalano V, Ferraù F, Massacesi C, Labianca R, Santini D, Silva RR, Zaniboni A, Antognoli S, Barni S, Siena S, Graziano F, Maisano R , Priolo D, Battelli N, Pessi MA, Giordani P, Mari D, Balzelli AM, Rota S, Cascinu S
    • Proc.ASCO, 145a, abst. 576, 2001
  11. “Effectiveness of low Molecular Weight Heparin (LMWH) in Cancer-Related Disseminated Intravascular Coagulation (DIC). A Case Report.”
    • Vitale F, Priolo D, Sambataro D, Colina P, Ferraù F
    • Haemostasis, 31(suppl 1), abst. PO 33, pag. 95-96, 2001 (copia)
  12. “Cancer-Related Mild Disseminated Intravascular Coagulation (Mild DIC): A Possible Role for Nadroparin Therapy”
    • Vitale F, Priolo D, Rotondo S, Mattina M, Ferraù F
    • Haemostasis, 31(suppl 1), abst. PO 34, pag. 96, 2001 (copia)
  13. “ Chemotherapy for transitional cell carcinoma (TCC) patients (pts) unsuitable to cisplatin: a phase II study of gemcitabine (G) and vinorelbine (V) combination.”
    • Mattina M, Amadio P, Caristi N, Colina P, Parisi A, Priolo D, Sambataro D, Tralongo P, Maisano R, Ferraù F
    • Ann Oncol , 12(suppl.4) , C11:33, 2001
  14. “Inteleukin-2 (IL-2), Interferon a-2° (IFNa) and bolus fluorouracil (5FU) in renal cell carcinoma(RCC) patients (pts).”
    • Lavenia G, Gambera G, Giuffrida D, Aiello RA, Bordonaro R, Ferraù F, Failla G, Mattina M
    • Ann Oncol , 12(suppl.4) , C20: 35, 2001
  15. “Dose intensification of gemcitabine in nsclc stage IIIb and IV. A phase II study.”
    • Gareri R, Calì S, Ferraù F, Priolo D, Lembo A, Paoluzzi L, Cortesi E
    • Ann Oncol , 12(suppl.4) , F16: 64, 2001
  16. “Chemo-hormonotherapy of advanced medullary thyroid carcinoma (MTC): our experience.”
    • Giuffrida D, Lavenia G, Aiello RA, Bordonaro R, Cordio S, Ferraù F, Pappalardo A, Priolo D, Failla G
    • Ann Oncol , 12(suppl.4) , G19: 74, 2001
  17. “Gemcitabine (G) as a six-hour infusion in patients (pts) with metastatic, largely treated, solid tumours.”
    • Ferraù F, Antonelli G, Calì S, Colina P, Malaponte E, Mattina M, Parisi A, Sambataro D, Tralongo P, Vitale F, Priolo D
    • Ann Oncol , 12(suppl.4) , I19: 89, 2001
  18. “CMF hepatic toxicity can be reduced by SAMe (S-adenosyl-L-methionine) administration.”
    • Tralongo P, Di Mari A, Moruzzi G, Conti G, Aiello R, Risicato R, Ferraù F, Scifo G, Failla G
    • Eur J Can 37(suppl6), 1328:S357, 2001
  19. “A multicenter randomized phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell lung cancer (SCLC): preliminary results.”
    • De Marinis F, Gridelli C, Lombardo M, Paoluzzi L, Ferraù F, Barbera S, Bertetto O, Barni S, Michetti G, Labianca R, Recchia F, Mattioli R, Martelli O, Rizzotto V,
    • Proc.ASCO, 305a , abst. 1219, 2002
  20. “ Phase I-II study of liposomial doxorubicin and docetaxel as first line treatment in patients with advanced breast cancer.”
    • Gasparini G, Morabito A, Fanelli M, Gattuso D, Bonginelli P, Vitale S, Longo R, De Sio L, Magnani E, Priolo D, Ferraù F
    • Proc.ASCO, 54b , abst. 2029, 2002
  21. “ Phase I-II study of gemcitabine and vinorelbine as second line treatment of patients with metastatic breast cancer.”
    • Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagone V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G
    • Proc.ASCO, 63b , abst. 2064, 2002
  22. “Lack of resistence to oxaliplatin (L-OHP)-based chemotherapy in patients (pts) with advanced gastric cancer previously treated with cisplatin-containing regimens: preliminary results of a phase II study.”
    • Catalano V, Graziano F, Salvagni S, Ferraù F, Poletti P, Maisano R, Pucci F, Baldelli AM, Labianca R, Lai V, Catalano G, Cascinu S
    • Proc.ASCO, 97b , abst. 2200 , 2002
  23. “Fluorouracile infusionale, acido folinico ed oxaliplatino nel ca-mammario antracicline – taxani resistente”
    • Ferraù F, Priolo D, Malaponte E
    • Atti Eloxatin Meeting – Italy, pp.40-42 , Milano 4-5 Aprile 2002
  24. “La neutropenia”
    • Ferraù F, Priolo D, Sambataro D
    • Atti del Convegno “Qualità di Vita e Controllo dei Sintomi” , pp.82-84 , Siracusa 6 Luglio 2002
  25. “Il caregiver di sesso femminile contribuisce a gestire lo stato di ansia o di depressione dell’oncologico in trattamento chemioterapico”
    • Giardina S, Lissandrello G, Rocco Genoano V, Respini D, Conti G, Di Mari A, Moruzzi G, Maceri G, Ferraù F, Tralongo P.
    • Atti del Convegno “Qualità di Vita e Controllo dei Sintomi” , pp.125-126 , Siracusa 6 Luglio 2002
  26. “Phase I-II study of liposomial doxorubicin (Caelyx) and docetaxel as first line treatment in patients with metastatic breast cancer”
    • Gattuso D, Morabito A, Ferraù F, De Sio L, Costellana M, Fanelli M, Capaccetti B, Sarmento B, Antonelli G, Gasparini G
    • Ann Oncol 13(suppl.3), A19, p.7 , 2002 (copia)
  27. “The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer (mbc) pretreated with taxanes and/or anthracyclines: a phase I-II study.”
    • Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G
    • Ann Oncol 13(suppl.3), A20, p.7 , 2002 (copia)
  28. “Oxaliplatin (l-ohp), folinic acid (fa) and fluorouracil (5fu) for advanced breast cancer (bc) patients (pts) refractory to anthacyclines (ant) and taxanes (tax) .”
    • Ferraù F, Amadio P, Antonelli G, Calì S, Colina P, Malaponte E, Mattina M, Parisi A, Priolo D, Sambataro D, Tralongo P.
    • Ann Oncol 13(suppl.3), A30, p.10 , 2002 (copia)
  29. “Folfox-2 in patients with advanced gastric cancer previously treated with cisplatin- containing regimens: preliminary results of a phase II study.”
    • Catalano V, Graziano F, salvagni S, Poletti P, Ferraù F, Baldelli AM, Giordani P, Maisano R, Barni S, Pucci F, Labianca R
    • Ann Oncol 13(suppl.3), A53, p.47 , 2002 (copia)
  30. “ The female caregiver contributes to reduce the state of anxiety and depression of cancer patient in chemotherapeutic treatment” .
    • Giardina S, Lissandrello G, Genzano Rocco V, Respini D, Cafiso R, Conti G, Dimari A, Mauceri G, Ferraù F, Tralongo P
    • Ann Oncol 13(suppl.3), D25, p.55 , 2002 (copia)
  31. “Low molecular weight heparin (lmwh) therapy for cancer patients (pts) with chronic disseminated intravascular coagulation”
    • Vitale F, Antonelli G, Colina P, Mattina M, Priolo D, Rotondo S, Ferraù F
    • Ann Oncol 13(suppl.3), D47, p.60 , 2002 (copia)
  32. “Liposomial doxorubicin and docetaxel as first line therapy in patients with metastatic breast cancer”
    • Gasparini G, Gattuso D, Morabito A, De Sio L, Castellana M, Fanelli M, Capacetti B, Sarmiento R, Antonelli G, Ferraù F
    • Ann Oncol 13(suppl.5), 197P, p.55 , 2002 (copia)
  33. “Safety of oxaliplatin (l-ohp) with fluorouracil (5fu) and folinic acid (fa) for advanced breast cancer (bc pts) refractory to anthracyclines (ant) and taxanes (tax).”
    • Ferraù F, Amadio P, Antonelli G, Colina P, Malaponte E, Mattina M, Priolo D, Tralongo P, Vitale F .
    • Ann Oncol 13(suppl.5), 246, p.68 , 2002 (copia)
  34. “A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell lung cancer (SCLC): preliminary results.”
    • De Marinis F, Gridelli C, Lombardo M, Paoluzzi L, Ferraù F., Barbera S, Berretto O, Barni S, Michetti S, Labianca R
    • Ann Oncol 13(suppl.5), 486PD, p.133 , 2002 (copia)
  35. “ Cisplatin (CDDP), gemcitabine (GEM), and paclitaxel (TAX) or vinorelbine (VNR) in metastatic carcinoma of unknown primary (cup). “
    • Palmeri S, Misino A, Accurso V, Ferraù F, Manuguerra G, Danova M, Nortilli R, Comella G, Filippelli G, Decataldis G .
    • Proc.ASCO, 239 , abst. 959, 2003
  36. “Rofecoxib associated with an antiangiogenic schedule of weekly irinotecan and infusional 5- fluorouracil as second line treatment of patients with metastatic colorectal cancer: results of a dose-finding study”
    • Morabito A, Gattuso D, Sarmento R, Vitale S, De Sio L, Longo R, Capaccetti B, Gamucci T, Ferraù F, Gasparini G .
    • Proc.ASCO, 326 , abst. 1311, 2003
  37. “Sequential vinorelbine (VNB) and gemcitabine (GEM) administration in elderly of unfit patients (pts) affected by advanced non small cell lung cancer (NSCLC).”
    • Ferraù F , Priolo D, Antonelli G, Calì S, Colina P, Mattina M, Vitale F, Amadio P
    • Proc.ASCO, 676 , abst. 2719, 2003
  38. “Antiangiogenic therapy with celecoxib and weekly palitaxel as second line treatment for advanced non small cell lung cancer (NSCLC): A phase II study”
    • Stani SC, Mansueto G, Comella G, Ferraù F, Capaccetti B, Carillo G, Magnani E, Locopo N, Vitale S, Gasparini G .
    • Proc.ASCO, 687 , abst. 2763, 2003
  39. “Farmaci antineoplastici“
    • Colina P, Ferraù F
    • Atti del II° Corso di Aggiornamento Post-Specialistico su “Early-Pregnancy” e III° Congresso Mediterraneo di Scienze Mediterraneo di Scienze Ginecologiche, Catania 8-10 Giugno 2003
  40. “La mucosite in Oncologia Medica: caratterizzazione, prevenzione e trattamento”
    • Amadio P, Priolo D, Colina P, Ferraù F
    • Atti del Convegno su “Le mucositi nel paziente oncologico. Prevenzione e trattamento” , Catania 28 Giugno 2003 , pagg.38-46 (copia)
  41. “L’anticoagulazione ha anche un ruolo antitumorale? Dalla terapiadella complicanza alla terapia della patologia di base.”
    • Vitale F, Priolo D, Amadio P, Colina P, Ferraù F
    • Baselife Oncology , 3:2, 22-23, 2003 (copia)
  42. “A retrospective analysis of the outcome of patients who have received gefitinib (‘Iressa’, ZD1839) after two or more prior chemotherapy regimens for recurrent non- small-cell lung cancer”
    • Antonelli G, Amadio P, Ferraù F
    • Iressa Clinical Experience (ICE) Meeting, Abstract book, abst.107, 2003 (copia)
  43. “A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as firt line treatment in patients with small cell lung cancer (SCLC): preliminary results”
    • De Marinis F, Gridelli C, Lombardo M, Paoluzzi L, Ferraù F, Barbera S, Bertetto O, Barni S, Labianca R, Nelli F
    • Lung Cancer, 41(suppl.):S81-S82, abst..O-279, 2003 (copia)
  44. “Second line treatment of antiangiogenic therapy with celecoxib and weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)”
    • Stani SC, Sarmiento R, Mansueto G, Bonginelli P, Comella G, Ferraù F, Magnani E, Carillo G, Sciacca V, Gasparini G
    • Lung Cancer, 41(suppl.):S181, abst..P-353, 2003 (copia)
  45. “Primary thromboprophylaxis with calcium nadroparin in metastatic breast cancer (Mbc) patients undergoing chemotherapy: a retrospective analysis”
    • Vitale F, Rotondo S, Amadio P, Parisi A, Priolo D, Ferraù F
    • Pathophysiol Haemost Thromb, 33(suppl. 1): 77-104, 2003 (copia)
  46. ”Vinorelbine (VNB) and gemcitabine (GEM) in unfit or elderly patients (pts) affected by advanced non small cell lung cancer (NSCLC): may sequential administration improve results?”
    • Amadio P, Priolo D, Antonelli G, Cali’ S, Colina P, Mattina M, Vitale F, Ferrau’ F
    • Eur J Cancer, 5(suppl.), p. S239, abst.795, 2003 (copia)
  47. “Trattamento adiuvante: ruolo della chemioterapia”
    • Priolo D, Ferraù F
    • Atti del Convegno su “Il carcinoma mammario nella donna anziana” , Catania 3 Ottobre 2003 , pagg.40-46, 2003 (copia)
  48. “Final results of a phase I-II study on the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer”
    • Morabito A, Gattuso D, Ferraù F, Castellana MA,Sarmiento R, Lorusso V, Carillo G, Lo Vullo S, Mariani L, Gasparini G
    • Ann Oncol, 14(suppl.4), p.ag.8, abst A26, 2003 (copia)
  49. “ Pegylated liposomal doxorubicin (PLD) plus 90’-infusional gemcitabine (iG) in malignant pleural mesothelioma (PM) patients (pts). A preliminary report.”
    • Cali’ S, Priolo D, Amadio P, Antonelli G, Colina P, Fuga’ P, Ferrau’ F
    • Ann Oncol, 14(suppl.4), p.ag.25, abst B40, 2003 (copia)
  50. “Raltitrexed plus levofolinic acid and bolus(continous infusion 5-fluorouracil on a biweekly schedule for advanced colorectal carcinomas (ACRC)”
    • Gebbia V, Verderame F, Ferraù F, Bordonaro R, Callari A, Caruso M, Tirrito ML, Valenza R, Cicero G, Borsellino N .
    • Ann Oncol, 14(suppl.4), p.ag.40, abst D26, 2003 (copia)
  51. “Rofecoxib associated with a weekly schedule of irinotecan and infusional 5- fluorouracil as second line treatment of patients with metastatic colorectal cancer: results of a phase I-II study”
    • Gattuso D, Morabito A, Sarmiento R, Vitale S, Longo R, Gamucci T, Ferraù F, Fanelli M, De Sio L, Gasparini G
    • Ann Oncol, 14(suppl.4), p.ag.42, abst D36, 2003 (copia)
  52. “Mild disseminated intravascular coagulation (mild dic) in cancer patients (pts) : a possible role for nadroparin therapy.”
    • Vitale F, Priolo D, Mattina M, Fuga’ M, Amadio P, Ferraù F
    • Ann Oncol, 14(suppl.4), p.ag.57, abst E32, 2003 (copia)
  53. “Prevalence and management of pain in patients with advanced non-small cell lung cancer”
    • Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera S, Robbiati SF, Ianniello GP, Ferraù F, Piazza E, Frontini L, Rosetti F, Iaffaioli RV, Perrone F on behalf of ELVIS, GEMVIn and MILES Investigators.
    • Ann Oncol, 14(suppl.4), p.ag.61, abst E50, 2003 (copia)
  54. “21-day topotecan continuous infusion (tci) for platinum-resistant relapsed ovarian carcinoma (roc) pretreated with platinum and paclitaxel - a phase-II study”
    • Priolo D, Scollo P, Amadio P, Antonelli G, Malaponte E, Scibilia G, Vitale F, Ferrau’ F.
    • Ann Oncol, 14(suppl.4), p.ag.70, abst F35, 2003 (copia)
  55. “Modulation of toxicity by sequential administration of vinorelbine (vnb) and gemcitabine (gem) in advanced non small cell lung cancer (nsclc) elderly or unfit patients (pts).”
    • Amadio P, Priolo D, Antonelli G, Cali’ S, Colina P, Malaponte E, Mattina M, Parisi A, Vitale F, Ferrau’ F
    • Ann Oncol, 14(suppl.4), pag.72, abst F40, 2003 (copia)
  56. “Topotecan as a 21-day continuous infusion (tci) in resistant/refractory ovairan carcinoma (roc)”
    • Ferraù F, Priolo D, Scollo P, Amadio P, Malaponte E, Mattina M, Scibilia G, Parisi A .
    • Abstracts XVII FIGO World COngress of Gynecology and Obstetrics, abst. WP49, pag. 83, 2003
  57. “Flurouracile infusionale, acido folinico ed Oxaliplatino nel carcinoma mammario antracicline-taxani resistente”
    • Ferraù F, Priolo D
    • Abstracts Convegno “Nuovi approcci nel trattamento del cancro”, Milano 17-19 Marzo 2004, pag.68 (copia)
  58. “Gemcitabina: standard europeo nel trattamento chemioterapico del carcinoma del Polmone non microcitoma”
    • Ferraù F, Antonelli G, Colina P, Priolo D
    • Abstract Book “First Messina Conference on Cancer Pharmacogenomics”, pagg. 75- 80, Messina 14-15 May 2004 (copia)
  59. “5-fluorouracil/folinic acid (lfa) and vinorelbine (vnr) in advanced breast carcinoma (mbc). A multicenter experience.”
    • Caruso M, Gebbia V, Ferraù F, Tralongo P, Borsellino N, Bordonaro R, Chiarenza M, Aiello R, Valenza R, Tirrito M, Verderame F, Agostara B
    • Ann Oncol, 15(suppl.2), pag.19, abst A43, 2004 (copia)
  60. “Trastuzumab (t) and vinorelbine (v) for patients (pts) with HER2-overexpressing advanced breast cancer (abc). A pilot phase II study.”
    • Ferraù F, Adamo V, Bordonaro R, Caristi N, Colina P, D’Angelo A, Garipoli C, Lavenia G, Priolo D, Rossello R, Tralongo P
    • Ann Oncol, 15(suppl.2), pag.25, abst A71, 2004 (copia)
  61. “Weekly docetaxel (txt) with weekly gemcitabine as prolonged infusion (gem) in patients with advanced, pretreated non-small-cell lung cancer (nsclc): preliminary report of a phase II study.”
    • Antonelli G, Priolo D, Amadio P, Colina P, Vitale F, Ferraù F
    • Ann Oncol, 15(suppl.2), pag.31, abst B16, 2004 (copia)
  62. “Alkylating agents in salvage therapy of platinum-resistant relapsed ovarian cancer (roc): still a worthwhile option.”
    • Priolo D, Colina P, Antonelli G, Vitale F, D’Angelo A, Malaponte E, Ferraù F
    • Ann Oncol, 15(suppl.2), pag.96, abst L26, 2004 (copia)
  63. “Low molecular weight heparin (lmwh) administration in cancer patients (pts) carrying brain metastases: a retrospective analysis.”
    • Vitale F, Priolo D, Rotondo S, Brmanti P, Antonelli G, Cali’ S, Parisi A, Colina P, Ferraù F.
    • Ann Oncol, 15(suppl.2), pag.117, abst N68, 2004 (copia)
  64. “Hepatic Arterial Infusion (HAI) of irinotecan (CPT 11) in Liver Metastatic Patients (LMP) with gastrointestinal malignancies: feasibility and tolerability of a weekly schedule”
    • Colina P, Antonelli G, Ferraù F, Vitale F
    • Abstract Book del III Corso Istituzionale SITILO e VII Congresso Nazionale SITILO “Trattamenti Innovativi e Locoregionali per Strategie Integrate in Oncologia”, pag. 54, Firenze 24-26 Novembre 2004 (copia)
  65. “Gemcitabine (GEM) and liposomal doxorubicin (PLD) in recurrent/metastatic breast carcinoma. A phase II study”
    • Adamo V, Ferrandina G, Spada M, Ferraù F, Condemi G, Di Lullo L, Lorusso D, Rossello R, Garipoli C, Scambia G
    • Proc.ASCO, 75s , abst. 790, 2005 (copia)
  66. “Weekly docetaxel (TXT) and prolonged infusion (PI) of gemcitabine (GEM): a promising therapeutic optino in patients with advanced, pretreated non-small cell lung cancer (NSCLC. A two stage SIMON designed phase I study.”
    • Antonelli G, Priolo D, Colina P, Vitale F, Ferraù F
    • Abstracts of the 11th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, S233-4, abst.P-445 (copia)
  67. “A metronomic treatment with oral vinorelbine in poor performace status patients with pretreated solid tumors”
    • Amadio P, Ferraù F, Colina P, Mare M, Blanco G, Caputo G, Lavenia G, Priolo D, Vitale F, Giuffrida D
    • Abstracts of European Cancer Conference (ECCO 13), Paris 30 October-3 November 2005 3:430, abst.1484 (copia);
  68. “Gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in recurrent 7 metastatic breast carcinoma: a phase II study.”
    • Ferrandina G, Adamo V, Ferraù F, Condemi G, Di Lullo L, Rosselo R, Lorusso D, Garipoli C, Scambia G
    • Ann Oncol, 16(suppl.7), pag.vii18, abst A45, 2005 (copia)
  69. “Metronomic schedale of oral vinorelbina in poor performance status patients with pretreated solid tumors”
    • Amadio P, Ferraù F, Colina P, Mare M, Blanco G, Mafodda A, Voltaggio G, Priolo D, Antonelli G, Giuffrida D
    • Ann Oncol, 16(suppl.7), pag.vii27, abst B33, 2005 (copia)
  70. “Greatly increased disease control rate in metastatic colon cancer patients undergoing first line Folfox 4 based chemotherapy regimen with concomitant heparinization: a retrospective Analysis”
    • Vitale F, Calì S, D’Angelo A, Giaimo V, Malaponte E, Parisi A, Ferraù F, Rotondo S
    • Abstracts 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo 14-16 October 2005, Haematologica 1:112, abst.P095 (copia)
  71. “Different expression of e-cadherin, beta-catenin and fibronectin in signet ring cell and intestinal colorectal carcinoma”
    • Sanguedolce R, Cabibi D, Rausa L, Ferraù F, Aragona F, Martorana A, Barresi E, Calascibetta A.
    • Ann Oncol, 17(suppl.9), pag.ix255, abst 872P, 2006 (copia)
  72. “Low molecular weight heparin (lmwh) in cancer patients (pts) carrying brain metastases (bm): a retrospective analysis”
    • Vitale F, Priolo D, Colina P, D‘Angelo A, Antonelli G, Giamo V, Parisi A, Cali’ S, Ferraù F .
    • Ann Oncol, 17(suppl.9), pag.ix287, abst 993P, 2006 (copia)
  73. “Combination of gemcitabine (gem) and liposomal peglated doxorubicin (pld) in recurrent/metastatic breast carcinoma: a phase II study.”
    • Adamo V, Ferrandina G, Rossello R, Garipoli C, Adamo B, Masi MC, Lorusso V, Condemi G, Ferraù F, Scambia G.
    • Ann Oncol, 17(suppl.9), pag.ix74, abst 160P, 2006 (copia)
  74. “Metronomic schedule of capecitabine (c) in poor performance status patients (pts) with pretreated solid tumors”
    • Amadio P, Ferraù F, Colina P, Rampello E, Mattina M, Sambataro D, Latteri F, SotoParra H, Priolo D, Cordio S
    • Ann Oncol, 17(suppl.9), pag.ix140-1, abst 425P, 2006 (copia)
  75. “Studio pilota di immunoterapia intraarteriosa con interferone a2b combinata con chemioterapia sistemica a base di florouracile, nei pazienti affetti da epatocarcinoma non responsivi e/o candidabili a trattamenti terapeutici convenzionali”
    • Vitale F, Calì S, D’Angelo A, Ferraù F, La Greca M, Parisi A, Squadrito G, Romeo P.
    • Atti del IX Congresso Nazionale S.I.T.I.L.O, Bologna 24-25 Novembre 2006 (copia)
  76. “Safety and convenience of cetuximab (cet) and irinotecan (iri) both given every two weeks in metastatic colorectal cancer (mcrc) patients (pts). Preliminary report.”
    • Colina P, Antonelli G, D’Angelo A, Giaimo V, Priolo D, Ferraù F
    • Ann Oncol, 18(suppl.6), pag.vi188, 2007 (copia)
  77. “Ibandronate (i) loading dose improves pain control in patients (pts) with bone metastases resistant to opioid treatment.”
    • Colina P, Antonelli G, Calì S, D’Angelo A, La Greca M, Priolo D, Ferraù F
    • Ann Oncol, 18(suppl.6), pag.vi194, 2007 (copia)
  78. “Bilateral testicular germ cell tumours: different therapeutic strategies for different challenging clinical scenarios”
    • D’Angelo A, Antonelli G, Colina P, La Greca M, Priolo D, Vitale F, Ferraù F
    • Ann Oncol, 18(suppl.6), pag.vi194, 2007 (copia)
  79. “Randomized phase II trial of two sequential schedules of docetaxel (D) and cisplatin (C) followed by gemcitabine (G) in patients with advanced non-small cell lung cancer.
    • E. Galligioni, V. Gebbia, G. Cartenì, T. Gamucci, F. Grossi, F. Ferraù, M. Nardi, C. Pollera, S. Rossi, F. De Marinis
    • Proc.ASCO, 867s , abst. 18154, 2007 (copia)
  80. “Sequential treatment of advanced non-small cell lung cancer with 2 schedules of docetaxel (d) and cisplatin (c) combination, followed by gemcitabine (g). Preliminary results of a randomized phase II trial”
    • E. Galligioni, V. Gebbia, G. Cartenì, T. Gamucci, F. Grossi, F. Ferraù , M. Nardi7, C. Pollera, O. Caffo, S. Rossi, B.Tedesco, F. De Marinis
    • Ann Oncol, 18(suppl.11), pag.xi36, abst.B52, 2007 (copia)
  81. “Low molecular weight heparin (LMWH) administration in patients suffering from pulmonary embolism and brain metastasis: a report of two cases”
    • Vitale F, Rotondo S, La Greca M, Parisi A, Giaimo V
    • Thrombosis Research, 120(suppl.2): s160, abst.PO-47, 2007 (copia)
  82. Multidisciplinar therapeutic strategies for bilateral testicular germ cell tumors. Case Reports”
    • D’Angelo A, Calì S, Giaimo V, La Greca M, Priolo D, Ferraù F
    • Archivio Italiano Urologia Andrologia, 79, 3, Supplemento 2, 2007 (copia)